Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.
- DOI
- 10.1038/s41408-026-01509-8
- Published
- 2026 May 7
- Container
- Blood cancer journal
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41408-026-01509-8,
title = {Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.},
author = {Timofeeva N and Herrera B and Fujiwara H and Asami T and Endo H and Hatakeyama M and Nakajima F and Ohmoto H and Nishioka Y and Miyamoto K and Arimura A and Tantawy SI and Pinilla-Ibarz J and Coombs CC and Jain N and Sawa M and Gandhi V},
year = {2026},
journal = {Blood cancer journal},
doi = {10.1038/s41408-026-01509-8},
url = {https://doi.org/10.1038/s41408-026-01509-8}
}RIS
TY - JOUR TI - Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations. AU - Timofeeva N AU - Herrera B AU - Fujiwara H AU - Asami T AU - Endo H AU - Hatakeyama M AU - Nakajima F AU - Ohmoto H AU - Nishioka Y AU - Miyamoto K AU - Arimura A AU - Tantawy SI AU - Pinilla-Ibarz J AU - Coombs CC AU - Jain N AU - Sawa M AU - Gandhi V PY - 2026 JO - Blood cancer journal DO - 10.1038/s41408-026-01509-8 UR - https://doi.org/10.1038/s41408-026-01509-8 ER -
APA
N, T., B, H., H, F., T, A., H, E., M, H., F, N., H, O., Y, N., K, M., A, A., SI, T., J, P., CC, C., N, J., M, S., & V, G. (2026). Docirbrutinib is a pan-mutant BTK inhibitor and inhibits B-cell receptor signaling in chronic lymphocytic leukemia cells in preclinical and early clinical investigations.. Blood cancer journal. https://doi.org/10.1038/s41408-026-01509-8
Source records
- pubmed · retrieved 2026-09-25T22:25:04.217Z